The ARSB Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout population derived from the SK-HEP-1 human liver adenocarcinoma cell line. Targeting the ARSB gene, which encodes the lysosomal enzyme arylsulfatase B, this knockout model disrupts the gene’s function without specifying the precise editing outcome, as it is a polyclonal pool. The cells are provided as a mixed population, facilitating robust functional studies where gene disruption is assessed at the population level. This format is suitable for applications requiring loss-of-function analysis in a heterogeneous cellular context.
The parental SK-HEP-1 cell line was originally established from the ascitic fluid of a patient with liver adenocarcinoma and is widely utilized as a hepatocellular carcinoma (HCC) model. It exhibits epithelial morphology and retains key features of malignant hepatocytes, including anchorage-independent growth and tumorigenicity in vivo. While not derived from primary hepatocytes, SK-HEP-1 cells express markers consistent with endothelial origin, yet they are functionally employed in HCC research. Their robust growth and adaptability make them a practical host for studying cancer-related processes, including lysosomal biology in hepatic malignancy.
ARSB functions as a lysosomal sulfatase critical for the degradation of sulfated glycosaminoglycans, specifically hydrolyzing sulfate esters from dermatan sulfate and chondroitin sulfate. Its expression is transcriptionally regulated by TFEB, a master regulator of lysosomal biogenesis, and its activity directly controls the levels of its substrates??dermatan sulfate and chondroitin sulfate??within the lysosomal compartment. ARSB operates within a coordinated pathway comprising iduronate-2-sulfatase, beta-glucuronidase, N-acetylgalactosamine-6-sulfatase, and hyaluronidase. Loss of ARSB disrupts this metabolic cascade, leading to accumulation of partially degraded glycosaminoglycans, a hallmark of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).
In the SK-HEP-1 background, ARSB knockout creates a unique hepatic cancer model with a defined lysosomal storage defect. The accumulation of dermatan sulfate and chondroitin sulfate may interfere with cellular signaling, extracellular matrix remodeling, and lysosomal homeostasis, potentially influencing cancer cell proliferation, migration, and drug sensitivity. This system allows dissection of the interplay between lysosomal dysfunction and hepatocellular carcinoma pathogenesis. Because the liver is a central organ for glycosaminoglycan metabolism, this model also provides insights into the hepatic manifestations of lysosomal storage disorders.
Researchers can employ these polyclonal cells for disease modeling of mucopolysaccharidosis type VI, investigation of lysosomal storage disorder mechanisms, and exploration of glycosaminoglycan turnover in cancer cells. The knockout pool is amenable to high-throughput drug screening for enzyme replacement therapies or small-molecule modulators. Representative assays include ARSB enzyme activity measurements, quantitative Western blotting and RT-qPCR, DMMB-based glycosaminoglycan quantification, immunofluorescence for LAMP1 to assess lysosomal expansion, lysosomal pH monitoring, transcriptomic profiling by RNA-seq, and drug sensitivity assays. For further information, please contact Ascent Research.
